AstraZeneca : Update on CRYSTALIZE evidence trials - Form 6-

a2725v

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

China , Japan , Denmark , Washington , United States , Cambridge , Cambridgeshire , United Kingdom , Danish , Sharon Barr , Coll Cardiol , Adrian Kemp , Securities Exchange , Nasdaq , European Medicines Agency Lokelma , Company Secretary , Astrazeneca , Astrazeneca Pharmaceuticals , Investor Relations Team , Diabetes Work Group , Commission File Number , Foreign Issuer , Securities Exchange Act , File Number , Crick Avenue , Regulationst Rule , Outcomes Phase , Executive Vice President , Rare Diseases , Dialysate Potassium Concentrations , Clinj Am Soc , Single Number , Communication Worldwide More , Individuals Have Kidney , Nephrol Dial , Global Burden , Disease Study , Heart Failure , American College , American Heart Association Joint Committee , Clinical Practice , Improving Global Outcomes , Diabetes Work , Treatment Gap Between Clinical Guidelines , Renin Angiotensin Aldosterone System , Trials Gov , Sodium Zirconium Cyclosilicate , Chronic Kidney Disease , Participants With , Arrythmia Related Cardiovascular Outcomes , Chronic Hemodialysis With Recurrent Hyperkalemia , Medicines Agency , Product Characteristics , Markets ,